首页> 外文会议>Conference on ultrasonic imaging and tomography >Development and Evaluation of a novel VEGFR2-targeted nanoscale ultrasound contrast agents
【24h】

Development and Evaluation of a novel VEGFR2-targeted nanoscale ultrasound contrast agents

机译:新型VEGFR2靶向纳米级超声造影剂的开发与评价

获取原文

摘要

Recent literatures have reported that the targeted nanoscale ultrasound contrast agents are becoming more and more important in medical application, like ultrasound imaging, detection of perfusion, drug delivery and molecular imaging and so on. In this study, we fabricated an uniform nanoscale bubbles (257 nm with the polydispersity index of 0.458) by incorporation of antibody targeted to vascular endothelial growth factor receptor 2 (VEGFR2) into the nanobubbles membrane by using avidin-biotin interaction. Some fundamental characterizations such as nanobubble suspension, surface morphology, particle size distribution and zeta potential were investigated. The concentration and time-intensity curves (TICs) were obtained with a self-made ultrasound experimental setup in vitro evaluation. In addition, in order to evaluate the contrast enhancement ability and the potential tumor-targeted ability in vivo, normal Wistar rats and nude female BALB/c mice were intravascular administration of the nanobubbles via tail vein injection, respectively. Significant contrast enhancement of ultrasound imaging within liver and tumor were visualized. These experiments demonstrated that the targeted nanobubbles is efficient in ultrasound molecular imaging by enhancement of the contrast effect and have potential capacity for targeted tumor diagnosis and therapy in the future.
机译:最近的文献报道称,目标纳米级超声造影剂在医学应用中变得越来越重要,例如超声成像,检测灌注,药物递送和分子成像等。在这项研究中,通过使用抗植物 - 生物素相互作用将靶向血管内皮生长因子受体2(VEGFR2)的抗体掺入抗体,我们通过使用抗体将靶向血管内皮生长因子受体2(VEGFR2)掺入纳米泡膜的抗体来制造均匀的纳米级气泡(具有0.458的多分散性指数。研究了一些基本表征,例如纳米泡悬浮液,表面形态,粒度分布和Zeta电位。用自制超声实验设置在体外评估中获得浓度和时间强度曲线(TICS)。此外,为了评估体内的对比增强能力和潜在的肿瘤靶向能力,正常的Wistar大鼠和裸体雌性BALB / C小鼠分别通过尾静脉注射血管内施用纳米杆状物。可视化肝脏和肿瘤内超声成像的显着对比度。这些实验证明,通过增强对比效果,靶向纳米博布尔在超声分子成像中有效,并具有未来靶向肿瘤诊断和治疗的潜在能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号